Improving access to clinical trials
Clinical trials are the single best way to turn advances in science into patient benefits. The ICR has a vision that a suitable trial should be made available for every person with cancer who wants to be part of one.
Expanding trial access – ICR report
Our 2021 report, Clinical trials in cancer, reveals the impact of the Covid-19 pandemic on cancer trials and highlights longstanding barriers to expanding clinical trial access to more people with cancer. But Covid-19 also offers clues to a recovery that can get new treatments to cancer patients more quickly.
News: Cancer trial recruitment drops by 60 per cent during pandemic
The number of cancer patients entering clinical trials has plummeted during the pandemic – denying many thousands the latest treatment options and delaying drug development. Here, cancer experts set out their findings about the barriers to carrying out clinical trials in the UK and proposals for boosting participation.Latest ICR News
New drug combination to tackle advanced prostate cancer
Up to two in five advanced prostate cancer patients could be treated with a combination of two targeted drugs, according to new research.
New research identifies a more accurate way of predicting which blood cancer patients will relapse early
Scientists have identified a more accurate way of predicting which patients with multiple myeloma, a type of blood cancer, are likely to relapse early following treatment.
Stress may increase cancer risk in people with inherited cancer genes
Suffering from psychological stress could further increase cancer risk in those already genetically predisposed to the disease, according to new research.
Two new fast-growing oncology companies join the Innovation Gateway at the London Cancer Hub
Two new oncology companies, Kindling Bio and Beckman Coulter, have been secured as tenants at the Innovation Gateway, a leading life sciences incubator at the heart of the London Cancer Hub.